Integrated cross-species transcriptional network analysis of metastatic susceptibility

Metastatic disease is the proximal cause of mortality for most cancers and remains a significant problem for the clinical management of neoplastic disease. Recent advances in global transcriptional analysis have enabled better prediction of individuals likely to progress to metastatic disease. However, minimal overlap between predictive signatures has precluded easy identification of key biological processes contributing to the prometastatic transcriptional state. To overcome this limitation, we have applied network analysis to two independent human breast cancer datasets and three different mouse populations developed for quantitative analysis of metastasis. Analysis of these datasets revealed that the gene membership of the networks is highly conserved within and between species, and that these networks predicted distant metastasis free survival. Furthermore these results suggest that susceptibility to metastatic disease is cell-autonomous in estrogen receptor-positive tumors and associated with the mitotic spindle checkpoint. In contrast, nontumor genetics and pathway activities-associated stromal biology are significant modifiers of the rate of metastatic spread of estrogen receptor-negative tumors. These results suggest that the application of network analysis across species may provide a robust method to identify key biological programs associated with human cancer progression.

[1]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[2]  G. Rubin,et al.  A computer program for aligning a cDNA sequence with a genomic DNA sequence. , 1998, Genome research.

[3]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[4]  K. Broman,et al.  Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. , 2001, Cancer research.

[5]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[6]  Jerard Hurwitz,et al.  A Mammalian Bromodomain Protein, Brd4, Interacts with Replication Factor C and Inhibits Progression to S Phase , 2002, Molecular and Cellular Biology.

[7]  Edison T Liu,et al.  A bioinformatics-based strategy identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers. , 2002, Genome research.

[8]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[9]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[10]  Richard Simon,et al.  A random variance model for detection of differential gene expression in small microarray experiments , 2003, Bioinform..

[11]  She Chen,et al.  Phosphorylation of Cdc20 by Bub1 provides a catalytic mechanism for APC/C inhibition by the spindle checkpoint. , 2004, Molecular cell.

[12]  T. Veenstra,et al.  Caffeine suppresses metastasis in a transgenic mouse model: a prototype molecule for prophylaxis of metastasis , 2005, Clinical & Experimental Metastasis.

[13]  R. Dickson,et al.  Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice , 2004, In Vitro Cellular & Developmental Biology - Animal.

[14]  Nengjun Yi,et al.  The Collaborative Cross, a community resource for the genetic analysis of complex traits , 2004, Nature Genetics.

[15]  Eytan Domany,et al.  Outcome signature genes in breast cancer: is there a unique set? , 2004, Breast Cancer Research.

[16]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[17]  J. Castle,et al.  An integrative genomics approach to infer causal associations between gene expression and disease , 2005, Nature Genetics.

[18]  N. Crawford,et al.  Metastasis Predictive Signature Profiles Pre-exist in Normal Tissues , 2005, Clinical & Experimental Metastasis.

[19]  P. Pharoah,et al.  Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1 , 2005, Nature Genetics.

[20]  J. Thierry-Mieg,et al.  AceView: a comprehensive cDNA-supported gene and transcripts annotation , 2006, Genome Biology.

[21]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[22]  L. Ein-Dor,et al.  Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[23]  I. Ellis,et al.  An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer , 2007, Genome Biology.

[24]  Jinghui Zhang,et al.  Rrp1b, a New Candidate Susceptibility Gene for Breast Cancer Progression and Metastasis , 2007, PLoS genetics.

[25]  R. Lidereau,et al.  Gene arrays for diagnosis, prognosis and treatment of breast cancer metastasis , 2007, Clinical & Experimental Metastasis.

[26]  M. Kirschner,et al.  Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation , 2007, Nature.

[27]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[28]  Steve Horvath,et al.  Network module detection: Affinity search technique with the multi-node topological overlap measure , 2009, BMC Research Notes.

[29]  N. Crawford,et al.  Bromodomain 4 activation predicts breast cancer survival , 2008, Proceedings of the National Academy of Sciences.

[30]  H. Kölbl,et al.  The humoral immune system has a key prognostic impact in node-negative breast cancer. , 2008, Cancer research.

[31]  Robert W. Williams,et al.  The Diasporin Pathway: a tumor progression-related transcriptional network that predicts breast cancer survival , 2008, Clinical & Experimental Metastasis.

[32]  B. Williams,et al.  Mapping and quantifying mammalian transcriptomes by RNA-Seq , 2008, Nature Methods.

[33]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[34]  A. Heck,et al.  Human Ccr4-Not complexes contain variable deadenylase subunits. , 2009, The Biochemical journal.

[35]  N. Crawford,et al.  The origins of breast cancer prognostic gene expression profiles. , 2009, Cancer research.

[36]  J. Foekens,et al.  Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study , 2009, Breast Cancer Research.

[37]  R. M. Simpson,et al.  Deletion of the proline-rich region of the murine metastasis susceptibility gene Brd4 promotes epithelial-to-mesenchymal transition- and stem cell-like conversion. , 2011, Cancer research.

[38]  F. Levi-Schaffer,et al.  CD48: A co-stimulatory receptor of immunity. , 2011, The international journal of biochemistry & cell biology.

[39]  Albert-László Barabási,et al.  Controllability of complex networks , 2011, Nature.

[40]  Johan Staaf,et al.  GOBO: Gene Expression-Based Outcome for Breast Cancer Online , 2011, PloS one.

[41]  Jennifer A. Smith,et al.  The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3 , 2011, Molecular and Cellular Biology.